GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Debt-to-Revenue

Amryt Pharma (Amryt Pharma) Debt-to-Revenue : 0.87 (As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Amryt Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $1.0 Mil. Amryt Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $211.8 Mil. Amryt Pharma's annualized Revenue for the quarter that ended in Sep. 2022 was $244.5 Mil. Amryt Pharma's annualized Debt-to-Revenue for the quarter that ended in Sep. 2022 was 0.87.


Amryt Pharma Debt-to-Revenue Historical Data

The historical data trend for Amryt Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Debt-to-Revenue Chart

Amryt Pharma Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.83 1.11 3.10 1.03 0.90

Amryt Pharma Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.91 0.87 0.79 0.87

Competitive Comparison of Amryt Pharma's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amryt Pharma's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Debt-to-Revenue falls into.



Amryt Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Amryt Pharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 199.183) / 222.543
=0.90

Amryt Pharma's annualized Debt-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.966 + 211.825) / 244.504
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2022) Revenue data.


Amryt Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Amryt Pharma (Amryt Pharma) Business Description

Traded in Other Exchanges
N/A
Address
196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).